AndreaBozzo/ceres-open-data-index huggingface dataset:
Sepsis-related organ failure assessment and withholding or withdrawing life support from critically ill patients

Background:
          We studied the incidence of withholding or withdrawing therapeutic measures in intensive care unit (ICU) patients, as well as the possible implications of sepsis-related organ failure assessment (SOFA) in the decision-making process and the ethical conflicts emerging from these measures.
        
        
          Methods:
          The patients (n = 372) were placed in different groups: those surviving 1 year after ICU admission (S; n = 301), deaths at home (DH; n = 2), deaths in the hospital after ICU discharge (DIH; n = 13) and deaths in the ICU (DI; n = 56). The last group was divided into the following subgroups: two cardiovascular deaths (CVD), 20 brain deaths (BD), 25 deaths after withholding of life support (DWH) and nine deaths after withdrawal of life support (DWD).
        
        
          Results:
          APACHE III, daily therapeutic intervention scoring system (TISS) and daily SOFA scores were good mortality predictors. The length of ICU stay in DIH (20 days) and in DWH (14 days) was significantly greater than in BD (5 days) or in S (7 days). The number of days with a maximum SOFA score was greater in DWD (5 days) than in S, BD or DWH (2 days).
        
        
          Conclusions:
          Daily SOFA is a useful parameter when the decision to withhold or withdraw treatment has to be considered, especially if the established measures do not improve the clinical condition of the patient. Although making decisions based on the use of severity parameters may cause ethical problems, it may reduce the anxiety level. Additionally, it may help when considering the need for extraordinary measures or new investigative protocols for better management of resources.
2013 CMHS Uniform Reporting System (URS) Table for New York

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for New York for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program.  State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Illicit Drug Use Tables (Standard Errors and P Values) - 1.1 to 1.92

These detailed tables present standard errors for illicit drug use totals and prevalence estimates from the 2011 National Survey on Drug Use and Health (NSDUH). Illicit drugs include marijuana, cocaine, crack, heroin, hallucinogens, inhalants, and the nonmedical use of prescription-type psychotherapeutics, including pain relievers, tranquilizers, stimulants, and sedatives. Standard errors are provided for lifetime, past year, and past month use by age group, gender, race/ethnicity, education level, employment status, and geographic area. Standard errors are provided for both 2011 and 2010.
Annual Report of State Child Welfare Expenditures

Each year, the Children's Bureau produces the Annual Report to Congress on State Child Welfare Expenditures Reported on the CFS-101s.

2024 Content |  Download (PDF)

2023 Content | 	
		Download (PDF)

2022 Content | 	
		Download (PDF)

2021 Content | 	
		Download (PDF)

2020 Content | 	
		Download (PDF)

2019 Content | 	
		Download (PDF)

2017 Content | 	
		Download (PDF)

2016 Content | 	
		Download (PDF)

2015 Content | 	
		Download (PDF)

2014 Content | Download (PDF) (2,003 KB)

2013 Content | Download (PDF) (594 KB)

2012 Content | Download (PDF) (566.4 KB)

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 528283: 2-(2-Propynylamino)-5-chloro-benzophenone

Chemical compound data from PubChem database. IUPAC Name: [5-chloro-2-(prop-2-ynylamino)phenyl]-phenylmethanone. Molecular Formula: C16H12ClNO. Molecular Weight: 269.72. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
North Dakota (ND)

This report presents North Dakota\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for North Dakota for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Determinants of patient recruitment in a multicenter clinical trials group: trends, seasonality and the effect of large studies

Background
          We examined whether quarterly patient enrollment in a large multicenter clinical trials group could be modeled in terms of predictors including time parameters (such as long-term trends and seasonality), the effect of large trials and the number of new studies launched each quarter. We used the database of all clinical studies launched by the AIDS Clinical Trials Group (ACTG) between October 1986 and November 1999. Analyses were performed in two datasets: one included all studies and substudies (n = 475, total enrollment 69,992 patients) and the other included only main studies (n = 352, total enrollment 57,563 patients).
        
        
          Results
          Enrollment differed across different months of the year with peaks in spring and late fall. Enrollment accelerated over time (+27 patients per quarter for all studies and +16 patients per quarter for the main studies, p < 0.001) and was affected by the performance of large studies with target sample size > 1,000 (p < 0.001). These relationships remained significant in multivariate autoregressive modeling. A time series based on enrollment during the first 32 quarters could forecast adequately the remaining 21 quarters.
        
        
          Conclusions
          The fate and popularity of large trials may determine the overall recruitment of multicenter groups. Modeling of enrollment rates may be used to comprehend long-term patterns and to perform future strategic planning.
Compound 526776: 7-Hydroxy-heptadecanoic acid, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 7-[tert-butyl(dimethyl)silyl]oxyheptadecanoate. Molecular Formula: C24H50O3Si. Molecular Weight: 414.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Child Care Licensing Study, 2007

The purpose of the 2007 Child Care Licensing Study is to report four aspects of child care licensing from 2007 for all 50 states and the District of Columbia: (1) state child care licensing programs and policies, (2) child care center licensing regulations, (3) small family child care home licensing regulations, and (4) large/group family child care home licensing regulations. 

To collect information on states' licensing policies, including staffing, monitoring, and enforcement of licensing regulations, the National Association for Regulatory Administration (NARA) disseminated the 2007 NARA Child Care Licensing Program Survey to all state child care licensing agencies in July 2007. Responses were received from all states. The survey focused on the processes and policies in each state related to staffing for the licensing program, monitoring facilities, and enforcement of licensing regulations. 

<b>Units of Response: </b>State 

<b>Type of Data: </b>Survey 

<b>Tribal Data: </b>No 

<b>Periodicity: </b>One-time  

<b>Demographic Indicators: </b>Not Applicable

<b>SORN: </b> https://www.federalregister.gov/documents/2022/01/24/2022-01066/privacy-act-of-1974-system-of-records 

<b>Data Use Agreement: </b>Unavailable 

<b>Data Use Agreement Location: </b> Not Applicable 

<b>Granularity: </b>State 

<b>Spatial: </b>United States 

<b>Geocoding: </b>Unavailable
Identifying research priorities on infections in older adults: proceedings of an interdisciplinary workshop

Background
          Infections pose a substantial burden to the health of older adults. In this report, we describe the proceedings of a workshop to formulate and prioritize research questions about infections in older adults using an interdisciplinary approach.
        
        
          Methods
          Researchers from four sectors (basic science, clinical sciences, health services and epidemiology/determinants of health) and representatives from various Canadian local, provincial, and federal stakeholder groups were invited to a two-day workshop. Five multi-disciplinary groups and stakeholders from each of three healthcare settings (long term, acute care and community) discussed research priorities for each of the settings. Five to ten research questions were identified for each setting.
        
        
          Results
          The research questions proposed ranged from risk factors and outcomes for different infections to the effect of nutrition on infection and the role of alternative and complementary medicine in treating infections. Health service issues included barriers to immunization, prolongation of hospital length of stay by infection, use of care paths for managing infections, and decision-making in determining the site of care for individuals with infections. Clinical questions included risk factor assessment for infection, the effectiveness of preventative strategies, and technology evaluation. Epidemiologic issues included the challenge of achieving a better understanding of respiratory infections in the community and determining the prevalence of colonization with multi-resistant bacteria.
        
        
          Conclusions
          The questions are of direct relevance to researchers in a wide variety of fields. Bringing together a multi-disciplinary group of researchers to frame and prioritize research questions about aging is feasible, participants valued the opinions of people working in other areas.
Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate

Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate is a generic prescription medication available as oral tablets in strengths like 1.25 mg, 1.875 mg, 2.5 mg, 3.125 mg, 3.75 mg, 5 mg, and 7.5 mg per component. Manufactured by NorthStar RxLLC and sponsored by Aurolife Pharma LLC under ANDA202424, it's a Schedule II controlled substance used as a central nervous system stimulant. This information was generated using AI and is provided for informational and research purposes only.
Compound 527128: 2,3-Dichloro-dibenzothiophene

Chemical compound data from PubChem database. IUPAC Name: 2,3-dichlorodibenzothiophene. Molecular Formula: C12H6Cl2S. Molecular Weight: 253.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Localities for 2024A

The CY 2024 Medicare Physician Fee Schedule has been updated by the annual PFS Final Rule for various new policies and for new and existing CPT/HCPCS codes.  For January 1, 2024, through March 8, 2024, the PFS conversion factor is $32.7442.  For March 9, 2024, through December 31, 2024, the CY 2024 Medicare Physician Fee Schedule has been updated by new legislation that revises the PFS conversion factor to $33.2875.
Medical informatics in an undergraduate curriculum: a qualitative study

Background
          There is strong support for educating physicians in medical informatics, and the benefits of such education have been clearly identified. Despite this, North American medical schools do not routinely provide education in medical informatics.
        
        
          Methods
          We conducted a qualitative study to identify issues facing the introduction of medical informatics into an undergraduate medical curriculum. Nine key informants at the University of Toronto medical school were interviewed, and their responses were transcribed and analyzed to identify consistent themes.
        
        
          Results
          The field of medical informatics was not clearly understood by participants. There was, however, strong support for medical informatics education, and the benefits of such education were consistently identified. In the curriculum we examined, medical informatics education was delivered informally and inconsistently through mainly optional activities. Issues facing the introduction of medical informatics education included: an unclear understanding of the discipline; faculty and administrative detractors and, the dense nature of the existing undergraduate medical curriculum.
        
        
          Conclusions
          The identified issues may present serious obstacles to the introduction of medical informatics education into an undergraduate medicine curriculum, and we present some possible strategies for addressing these issues.
Compound 525705: p-Methoxybenzylidene-heptyl-amine

Chemical compound data from PubChem database. IUPAC Name: N-heptyl-1-(4-methoxyphenyl)methanimine. Molecular Formula: C15H23NO. Molecular Weight: 233.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527227: (3R,3aR,5S,6R,7aR)-3,6,7,7-Tetramethyloctahydro-3a,6-ethanoinden-5-ol

Chemical compound data from PubChem database. IUPAC Name: 2,6,6,7-tetramethyltricyclo[5.2.2.01,5]undecan-8-ol. Molecular Formula: C15H26O. Molecular Weight: 222.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529357: Asn isoBOC TBDMS

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 4-amino-2-(2-methylpropoxycarbonylamino)-4-oxobutanoate. Molecular Formula: C15H30N2O5Si. Molecular Weight: 346.49. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528569: 4-Aminobenzoic acid, N-(tert-butyldimethylsilyl)-, tert-butyldimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 4-[[tert-butyl(dimethyl)silyl]amino]benzoate. Molecular Formula: C19H35NO2Si2. Molecular Weight: 365.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Utah 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Compound 529660: Methyl 11-methyl-6-methylidene-16-oxo-12,14-bis(trimethylsilyloxy)-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate

Chemical compound data from PubChem database. IUPAC Name: methyl 11-methyl-6-methylidene-16-oxo-12,14-bis(trimethylsilyloxy)-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate. Molecular Formula: C26H42O6Si2. Molecular Weight: 506.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528875: Benzaldehyde [4-((4-[(2E)-2-benzylidenehydrazino]phenyl)sulfonyl)phenyl]hydrazone

Chemical compound data from PubChem database. IUPAC Name: 1,1,1,3,3,3-hexafluoropropan-2-yl 2-(2,2,3,3,3-pentafluoropropanoylamino)-3-phenylpropanoate. Molecular Formula: C15H10F11NO3. Molecular Weight: 461.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401398-T1: [Translated] METHOD FOR PRODUCING POLYNUCLEOTIDE FRAGMENTS FOR USE IN SHUFFLING

The invention relates to a fragmentation process that depends on mismatches between two strands of parental polynucleotides. One embodiment, comprises a method for preparing polynucleotide fragments of DNA comprising formation of heteroduplex molecules by hybridizing polynucleotides. The invention also provides a method and process of forming fragments which can be used with any shuffling process or combination of shuffling processes.
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study

Background
          Limited information has been published regarding how specific processes for event adjudication can affect event rates in trials. We reviewed nonfatal myocardial infarctions (MIs) reported by site investigators in the international Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin (Eptifibatide) Therapy (PURSUIT) trial and those adjudicated by a central clinical events committee (CEC) to determine the reasons for differences in event rates.
        
        
          Methods
          The PURSUIT trial randomised 10,948 patients with acute coronary syndromes to receive eptifibatide or placebo. The primary end-point was death or post-enrolment MI at 30 days as assessed by the CEC; this end-point was also constructed using site-reported events. The CEC identified suspected MIs by systematic review of clinical, cardiac enzyme, and electrocardiographic data.
        
        
          Results
          The CEC identified 5005 (46%) suspected events, of which 1415 (28%) were adjudicated as MI. The site investigator and CEC assessments of whether a MI had occurred disagreed in 983 (20%) of the 5005 patients with suspected MI, mostly reflecting site misclassification of post-enrolment MIs (as enrolment MIs) or underreported periprocedural MIs. Patients for whom the CEC and site investigator agreed that no end-point MI had occurred had the lowest mortality at 30 days and between 30 days and 6 months, and those with agreement that a MI had occurred had the highest mortality.
        
        
          Conclusion
          CEC adjudication provides a standard, systematic, independent, and unbiased assessment of end-points, particularly for trials that span geographic regions and clinical practice settings. Understanding the review process and reasons for disagreement between CEC and site investigator assessments of MI is important to design future trials and interpret event rates between trials.
Patent AT-E40103-T1: [Translated] CYCLOHEXENEMETHANOL DERIVATIVE WITH MUCOSECRETOLYTIC ACTIVITY, ITS MANUFACTURING PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.

A novel derivative of (-)-6,6-dimethylbicyclo [3.1.1] ept-2- ene-2-ethanol (J.P. Bain. J. Am. Chem. Soc. 1946, Vol. 68, page 638) is disclosed. The patent composition is marketed e.g. under the name nopol, v. The Aldrich-Europe Catalog Handbook of Fine Chemicals, item 3160-5 nopol 98% 128-50-7.The object of the present invention is the compound of formula (I) : 4-(2-hydroxyethyl) -a a dimethyl-5-hydroxy-3-cyclohexene-1-methanol, with the process for obtaining the same. which consists of the preparation of (-)-(6,6-dimethylbicyclo[3.1.1.] ept-2-ene-2-ethanol epoxide, followed by hydration of the above compound. Finally, this invention comprises the pharmaceutical compositions con- taming the compound of formula (I) which have a mucosecretolytic pharmacological activity.
Compound 525620: N,N-Dimethyl-N'-cyclohexyl-p-methoxybenzamidine

Chemical compound data from PubChem database. IUPAC Name: N'-cyclohexyl-4-methoxy-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C16H24N2O. Molecular Weight: 260.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The C-terminal domain of the Bloom syndrome DNA helicase is essential for genomic stability

Background
          Bloom syndrome is a rare cancer-prone disorder in which the cells of affected persons have a high frequency of somatic mutation and genomic instability. Bloom syndrome cells have a distinctive high frequency of sister chromatid exchange and quadriradial formation. BLM, the protein altered in BS, is a member of the RecQ DNA helicase family, whose members share an average of 40% identity in the helicase domain and have divergent N-terminal and C-terminal flanking regions of variable lengths. The BLM DNA helicase has been shown to localize to the ND10 (nuclear domain 10) or PML (promyelocytic leukemia) nuclear bodies, where it associates with TOPIIIα, and to the nucleolus.
        
        
          Results
          This report demonstrates that the N-terminal domain of BLM is responsible for localization of the protein to the nuclear bodies, while the C-terminal domain directs the protein to the nucleolus. Deletions of the N-terminal domain of BLM have little effect on sister chromatid exchange frequency and chromosome stability as compared to helicase and C-terminal mutations which can increase SCE frequency and chromosome abnormalities.
        
        
          Conclusion
          The helicase activity and the C-terminal domain of BLM are critical for maintaining genomic stability as measured by the sister chromatid exchange assay. The localization of BLM into the nucleolus by the C-terminal domain appears to be more important to genomic stability than localization in the nuclear bodies.
Phoenix: Drug-Related Emergency Department Visits, 2004-2011 - Adverse Reactions

Excel file with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for emergency department visits involving adverse reactions in the Phoenix metropolitan area. It includes ED visits in which an adverse health consequence (e.g., side effects or an allergic reaction) resulted when taking prescription drugs, over-the-counter medications, or dietary supplements as prescribed or recommended.  This analytic category does not include drug misuse or abuse.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Compound 526018: Phenylethanolamine, N-DTFMB-TMS

Chemical compound data from PubChem database. IUPAC Name: N-(2-phenyl-2-trimethylsilyloxyethyl)-3,5-bis(trifluoromethyl)benzamide. Molecular Formula: C20H21F6NO2Si. Molecular Weight: 449.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.